Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration

Last updated: February 6, 2026
Sponsor: Pharmicell Co., Ltd.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Angina

Treatment

Hearticellgram-AMI

Clinical Study ID

NCT07400458
PMC-P-13
  • All Genders

Study Summary

This Long-term follow-up is designed to evaluate the safety of patient with Acute Myocardial Infarction who had administered Hearticellgram-AMI.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Those who had administered Hearticellgram-AMI

  2. Those who voluntarily agreed in writing to participate in this investigation

Exclusion

Exclusion Criteria:

Study Design

Total Participants: 100
Treatment Group(s): 1
Primary Treatment: Hearticellgram-AMI
Phase:
Study Start date:
March 03, 2022
Estimated Completion Date:
September 30, 2032

Study Description

To evaluate the safety for 60 months after a single dose of Hearticellgram-AMI in patients with Acute Myocardial Infarction.

Connect with a study center

  • KIMHYUNSOO Clinic

    Seoul 1835848, Gangnam 06017
    South Korea

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.